Metsera, Inc. - Common Stock (MTSR)
63.73
+0.00 (0.00%)
NASDAQ · Last Trade: Oct 31st, 8:09 AM EDT
Detailed Quote
| Previous Close | 63.73 | 
|---|---|
| Open | - | 
| Bid | 63.80 | 
| Ask | 64.00 | 
| Day's Range | N/A - N/A | 
| 52 Week Range | 12.30 - 66.10 | 
| Volume | 3,779 | 
| Market Cap | - | 
| PE Ratio (TTM) | -4.952 | 
| EPS (TTM) | -12.9 | 
| Dividend & Yield | N/A (N/A) | 
| 1 Month Average Volume | 1,702,762 | 
Chart
News & Press Releases
Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.
Via Stocktwits · October 31, 2025
Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.
Via Investor's Business Daily · October 30, 2025
Via Benzinga · October 30, 2025
Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metserastocktwits.com
Via Stocktwits · October 30, 2025
Novo Nordisk Submits Revised Bid For Metsera, Enters A Bidding War With Pfizerstocktwits.com
Via Stocktwits · October 30, 2025
Viking Therapeutics Ignites Retail-Trader Frenzy Amid Deal Speculation, Upcoming Trial Catalystsstocktwits.com
Via Stocktwits · October 6, 2025
Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential legal action.
Via Benzinga · October 30, 2025
Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · October 30, 2025
Via Benzinga · October 30, 2025
Via Benzinga · October 30, 2025
Income investors can capture yields above 5% from companies executing business transformations.
Via The Motley Fool · October 29, 2025
At least one of these stocks owned by Alphabet could be a great pick for aggressive investors.
Via The Motley Fool · October 27, 2025
Both companies are monsters in their industry and are poised to thrive.
Via The Motley Fool · October 25, 2025
  Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 
By Halper Sadeh LLC · Via GlobeNewswire · October 23, 2025
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Metsera, Inc. (NasdaqGS: MTSR) to Pfizer Inc. (NYSE: PFE). Under the terms of the proposed transaction, shareholders of Metsera will receive $47.50 per share in cash at closing, plus a non-transferable contingent value right entitling holders to potential additional payments of up to $22.50 per share in cash tied to three specific clinical and regulatory milestones. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
By Kahn Swick & Foti, LLC · Via Business Wire · October 23, 2025
Dividend stocks with high yields can be great investment opportunities, but those yields can also be red flags.
Via The Motley Fool · October 21, 2025
The company is readying to take on pharma giants Novo Nordisk and Eli Lilly.
Via The Motley Fool · October 13, 2025
Pfizer is working hard to deal with some big headwinds it has coming up, but in five years, this should all be in the past.
Via The Motley Fool · October 13, 2025
NEW YORK, Oct.  07, 2025  (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
By Halper Sadeh LLC · Via GlobeNewswire · October 7, 2025
BALA CYNWYD, Pa., Oct.  07, 2025  (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · October 7, 2025
Pfizer's stock price is down materially from its 2021 highs, but it is also up notably from its April 2025 lows.
Via The Motley Fool · October 7, 2025
After years of underperformance, the future is looking brighter for the drugmaker.
Via The Motley Fool · October 6, 2025
You don't need to be rich to put your money to work on Wall Street.
Via The Motley Fool · October 3, 2025
Pfizer has an attractive 7.2% dividend yield, but there are some pros and cons you need to understand before you buy it.
Via The Motley Fool · October 2, 2025